Responses
Interventional cardiology surgery
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty
Compose a Response to This Article
Other responses
No responses have been published for this article.